Bristol Myers Financials
| BMYB34 Stock | BRL 348.19 10.21 2.85% |
Bristol |
Understanding current and past Bristol Myers Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Bristol Myers' financial statements are interrelated, with each one affecting the others. For example, an increase in Bristol Myers' assets may result in an increase in income on the income statement.
Please note, the presentation of Bristol Myers' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bristol Myers' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Bristol Myers' management manipulating its earnings.
Bristol Myers Stock Summary
Bristol Myers competes with Roper Technologies,, DXC Technology, G2D Investments, Spotify Technology, and Unity Software. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. BRISTOLMYERSDRN operates under Drug Manufacturers - Major classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 23300 people.| Instrument | Brazil Stock View All |
| Exchange | Sao Paulo Exchange |
| Business Address | 430 East 29th |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Major |
| Benchmark | Dow Jones Industrial |
| Website | www.bms.com |
| Phone | 212 546 4000 |
| Currency | BRL - Brazilian Real |
You should never invest in Bristol Myers without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Bristol Stock, because this is throwing your money away. Analyzing the key information contained in Bristol Myers' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Bristol Myers Key Financial Ratios
Bristol Myers' financial ratios allow both analysts and investors to convert raw data from Bristol Myers' financial statements into concise, actionable information that can be used to evaluate the performance of Bristol Myers over time and compare it to other companies across industries.| Return On Equity | 0.18 | |||
| Return On Asset | 0.0613 | |||
| Number Of Employees | 41 | |||
| Beta | 0.42 | |||
| Z Score | 12.0 |
Bristol Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bristol Myers's current stock value. Our valuation model uses many indicators to compare Bristol Myers value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bristol Myers competition to find correlations between indicators driving Bristol Myers's intrinsic value. More Info.Bristol Myers Squibb is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.33 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Bristol Myers Squibb is roughly 3.01 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bristol Myers by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bristol Myers' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Bristol Myers Squibb Systematic Risk
Bristol Myers' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Bristol Myers volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Bristol Myers Squibb correlated with the market. If Beta is less than 0 Bristol Myers generally moves in the opposite direction as compared to the market. If Bristol Myers Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Bristol Myers Squibb is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Bristol Myers is generally in the same direction as the market. If Beta > 1 Bristol Myers moves generally in the same direction as, but more than the movement of the benchmark.
Bristol Myers January 12, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Bristol Myers help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bristol Myers Squibb. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bristol Myers Squibb based on widely used predictive technical indicators. In general, we focus on analyzing Bristol Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bristol Myers's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.86 | |||
| Information Ratio | 0.1495 | |||
| Maximum Drawdown | 16.96 | |||
| Value At Risk | (3.75) | |||
| Potential Upside | 3.26 |
Complementary Tools for Bristol Stock analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |